Neuropathophysiological Mechanisms and Treatment Strategies for Post-traumatic Epilepsy.

Shaunik Sharma, Grant Tiarks, Joseph Haight, Alexander G Bassuk
Author Information
  1. Shaunik Sharma: Medical Laboratories, Department of Pediatrics, University of Iowa, Iowa City, IA, United States.
  2. Grant Tiarks: Medical Laboratories, Department of Pediatrics, University of Iowa, Iowa City, IA, United States.
  3. Joseph Haight: Medical Laboratories, Department of Pediatrics, University of Iowa, Iowa City, IA, United States.
  4. Alexander G Bassuk: Medical Laboratories, Department of Pediatrics, University of Iowa, Iowa City, IA, United States.

Abstract

Traumatic brain injury (TBI) is a leading cause of death in young adults and a risk factor for acquired epilepsy. Severe TBI, after a period of time, causes numerous neuropsychiatric and neurodegenerative problems with varying comorbidities; and brain homeostasis may never be restored. As a consequence of disrupted equilibrium, neuropathological changes such as circuit remodeling, reorganization of neural networks, changes in structural and functional plasticity, predisposition to synchronized activity, and post-translational modification of synaptic proteins may begin to dominate the brain. These pathological changes, over the course of time, contribute to conditions like Alzheimer disease, dementia, anxiety disorders, and post-traumatic epilepsy (PTE). PTE is one of the most common, devastating complications of TBI; and of those affected by a severe TBI, more than 50% develop PTE. The etiopathology and mechanisms of PTE are either unknown or poorly understood, which makes treatment challenging. Although anti-epileptic drugs (AEDs) are used as preventive strategies to manage TBI, control acute seizures and prevent development of PTE, their efficacy in PTE remains controversial. In this review, we discuss novel mechanisms and risk factors underlying PTE. We also discuss dysfunctions of neurovascular unit, cell-specific neuroinflammatory mediators and immune response factors that are vital for epileptogenesis after TBI. Finally, we describe current and novel treatments and management strategies for preventing PTE.

Keywords

References

  1. Epilepsy Res. 2017 Oct;136:18-34 [PMID: 28753497]
  2. J Neurotrauma. 2012 Mar 20;29(5):851-64 [PMID: 22040225]
  3. Science. 2014 Oct 3;346(6205):89-93 [PMID: 25147279]
  4. Acta Neuropathol. 2010 Jan;119(1):7-35 [PMID: 20012068]
  5. Eur Neuropsychopharmacol. 2008 Mar;18(3):181-7 [PMID: 17669633]
  6. Front Neurosci. 2019 Sep 03;13:916 [PMID: 31551681]
  7. Neurochem Res. 2019 Jun;44(6):1410-1424 [PMID: 30661228]
  8. Neurochem Res. 2011 Mar;36(3):375-82 [PMID: 21136158]
  9. Handb Clin Neurol. 2015;127:45-66 [PMID: 25702209]
  10. Brain. 2005 Jan;128(Pt 1):174-88 [PMID: 15563512]
  11. Neuropharmacology. 2020 Aug 1;172:107907 [PMID: 31837825]
  12. J Neurosci. 2006 May 17;26(20):5438-47 [PMID: 16707796]
  13. N Engl J Med. 1998 Jan 1;338(1):20-4 [PMID: 9414327]
  14. J Neurotrauma. 2003 May;20(5):409-20 [PMID: 12803974]
  15. Cell Prolif. 2020 Mar;53(3):e12781 [PMID: 32035016]
  16. Epilepsy Res. 2010 Nov;92(1):74-84 [PMID: 20863664]
  17. Mediators Inflamm. 2015;2015:816460 [PMID: 26089604]
  18. Biomedicines. 2020 Sep 29;8(10): [PMID: 33003373]
  19. J Neurol. 2020 Oct;267(10):3105-3111 [PMID: 32444981]
  20. Epilepsy Res. 2002 Jun;50(1-2):179-89 [PMID: 12151127]
  21. Science. 2016 Feb 26;351(6276):933-9 [PMID: 26822608]
  22. Aging Dis. 2019 Jun 01;10(3):652-663 [PMID: 31165008]
  23. Exp Cell Res. 2017 Sep 1;358(1):31-38 [PMID: 28602626]
  24. Sci Rep. 2015 Sep 03;5:13497 [PMID: 26333872]
  25. Trends Immunol. 2015 Oct;36(10):569-577 [PMID: 26431936]
  26. PLoS One. 2011;6(7):e22899 [PMID: 21799943]
  27. Epilepsy Curr. 2006 Jan-Feb;6(1):1-5 [PMID: 16477313]
  28. Curr Neurol Neurosci Rep. 2015 May;15(5):27 [PMID: 25796572]
  29. Mol Neurodegener. 2017 Jan 17;12(1):7 [PMID: 28095923]
  30. Glia. 2012 Aug;60(8):1203-14 [PMID: 22378467]
  31. Epilepsy Curr. 2016 Nov-Dec;16(6):393-396 [PMID: 27857621]
  32. Br Med Bull. 1993 Jul;49(3):481-93 [PMID: 8221017]
  33. Science. 2010 Nov 5;330(6005):790-6 [PMID: 20929730]
  34. Eur J Immunol. 2013 Aug;43(8):2010-22 [PMID: 23630120]
  35. Neurochem Res. 2018 Oct;43(10):1978-1985 [PMID: 30173323]
  36. Cytokine Growth Factor Rev. 2006 Oct;17(5):381-409 [PMID: 16931108]
  37. Am J Pathol. 2005 Nov;167(5):1371-7 [PMID: 16251421]
  38. J Neurosci. 2020 Mar 11;40(11):2357-2370 [PMID: 32029532]
  39. J Neurochem. 1989 Feb;52(2):381-9 [PMID: 2911023]
  40. J Neurosci. 2012 Sep 12;32(37):12973-8 [PMID: 22973021]
  41. Nat Neurosci. 2007 Nov;10(11):1387-94 [PMID: 17965659]
  42. Neurotherapeutics. 2011 Apr;8(2):304-15 [PMID: 21431948]
  43. Nature. 1995 Jan 12;373(6510):123-6 [PMID: 7816094]
  44. Neuroscience. 2013 Oct 22;251:141-50 [PMID: 22522469]
  45. Nat Rev Neurol. 2011 Jan;7(1):31-40 [PMID: 21135885]
  46. J Neurochem. 2016 Apr;137(2):142-53 [PMID: 26809224]
  47. Neurology. 2010 Aug 31;75(9):792-8 [PMID: 20805525]
  48. Antioxid Redox Signal. 2015 Aug 10;23(5):406-27 [PMID: 24383718]
  49. F1000Res. 2019 Jan 28;8: [PMID: 30755793]
  50. Nature. 2017 Jan 26;541(7638):481-487 [PMID: 28099414]
  51. Oxid Med Cell Longev. 2015;2015:370312 [PMID: 25918580]
  52. J Neurotrauma. 2013 Aug 15;30(16):1434-41 [PMID: 23510201]
  53. Pediatr Res. 2007 Sep;62(3):271-6 [PMID: 17622965]
  54. J Neurosci. 1992 Dec;12(12):4846-53 [PMID: 1464770]
  55. Neurocrit Care. 2010 Apr;12(2):165-72 [PMID: 19898966]
  56. J Neuroinflammation. 2012 Apr 16;9:68 [PMID: 22507553]
  57. Curr Neuropharmacol. 2008 Sep;6(3):179-92 [PMID: 19506719]
  58. Neural Regen Res. 2014 Apr 1;9(7):688-92 [PMID: 25206873]
  59. Biochim Biophys Acta. 2016 Mar;1862(3):483-91 [PMID: 26655603]
  60. Int J Mol Sci. 2020 Jun 08;21(11): [PMID: 32521797]
  61. J Neurosci. 2017 Aug 16;37(33):7864-7877 [PMID: 28724747]
  62. Annu Rev Pharmacol Toxicol. 2015;55:229-47 [PMID: 25196047]
  63. Sci Rep. 2017 Aug 25;7(1):9459 [PMID: 28842681]
  64. J Clin Med. 2019 Dec 09;8(12): [PMID: 31818018]
  65. Hepatogastroenterology. 2007 Dec;54(80):2181-3 [PMID: 18265628]
  66. Free Radic Biol Med. 2006 Jan 15;40(2):316-22 [PMID: 16413413]
  67. Neurology. 2010 Jul 20;75(3):224-9 [PMID: 20644150]
  68. Acta Neuropathol Commun. 2014 Oct 20;2:143 [PMID: 25329434]
  69. Epilepsy Res. 2009 Jul;85(1):123-7 [PMID: 19369036]
  70. Annu Rev Immunol. 2012;30:677-706 [PMID: 22224761]
  71. Brain. 2016 Jul;139(Pt 7):1919-38 [PMID: 27289302]
  72. Arterioscler Thromb Vasc Biol. 2011 May;31(5):986-1000 [PMID: 21508345]
  73. Lancet. 2012 Sep 22;380(9847):1088-98 [PMID: 22998718]
  74. Neurobiol Dis. 2016 Sep;93:184-200 [PMID: 27208748]
  75. Neuroscience. 2006 Jun 30;140(2):685-97 [PMID: 16650603]
  76. Biochim Biophys Acta. 2015 Mar;1852(3):507-19 [PMID: 25460197]
  77. J Intensive Care. 2016 Apr 27;4:29 [PMID: 27123305]
  78. Front Physiol. 2020 Aug 21;11:1030 [PMID: 32973558]
  79. Rev Neurosci. 2018 Mar 28;29(3):333-345 [PMID: 29211683]
  80. Oxid Med Cell Longev. 2012;2012:795259 [PMID: 22848783]
  81. Epilepsia. 2015 Sep;56(9):1438-44 [PMID: 26332184]
  82. J Neuroinflammation. 2004 Jul 30;1(1):14 [PMID: 15285801]
  83. Neural Plast. 2019 May 6;2019:3259295 [PMID: 31198417]
  84. J Surg Res. 2012 Apr;173(2):e73-81 [PMID: 22172132]
  85. Crit Care. 2005 Feb;9(1):66-75 [PMID: 15693986]
  86. J Cereb Blood Flow Metab. 2002 Jun;22(6):735-45 [PMID: 12045672]
  87. Neurochem Res. 2017 Oct;42(10):2892-2901 [PMID: 28620825]
  88. Cell. 2006 May 19;125(4):775-84 [PMID: 16713567]
  89. Pathol Res Pract. 1984 Sep;179(1):7-12 [PMID: 6504770]
  90. J Child Neurol. 2018 Dec;33(14):909-917 [PMID: 30303442]
  91. Front Immunol. 2016 Dec 05;7:556 [PMID: 27994591]
  92. Cell Commun Signal. 2020 Apr 15;18(1):62 [PMID: 32293472]
  93. J Neurosci. 2005 Mar 23;25(12):3219-28 [PMID: 15788779]
  94. eNeuro. 2016 Feb 18;3(1): [PMID: 27022620]
  95. J Neuroinflammation. 2011 Jun 03;8:63 [PMID: 21639880]
  96. FASEB J. 2017 Apr;31(4):1273-1288 [PMID: 28087575]
  97. Int J Mol Sci. 2020 Oct 09;21(20): [PMID: 33050322]
  98. Neuron. 2010 Nov 4;68(3):409-27 [PMID: 21040844]
  99. J Neurotrauma. 2014 Aug 15;31(16):1439-43 [PMID: 24693960]
  100. Neurobiol Aging. 1995 Jan-Feb;16(1):53-7 [PMID: 7723936]
  101. Stroke. 2012 Nov;43(11):3063-70 [PMID: 22933588]
  102. Exp Neurol. 2005 Jun;193(2):481-8 [PMID: 15869950]
  103. Epilepsia. 1998 Jan;39(1):77-80 [PMID: 9578016]
  104. Neurosci Lett. 1991 Nov 11;132(2):212-6 [PMID: 1664504]
  105. J Neurol Neurosurg Psychiatry. 2003 Jan;74(1):39-43 [PMID: 12486264]
  106. Am J Physiol Cell Physiol. 2020 Jul 1;319(1):C64-C74 [PMID: 32401607]
  107. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):257-61 [PMID: 8093558]
  108. Cell. 2020 Aug 6;182(3):625-640.e24 [PMID: 32702313]
  109. Neurosci Res. 2006 Sep;56(1):103-10 [PMID: 16837093]
  110. J Neurol Neurosurg Psychiatry. 1999 Feb;66(2):207-13 [PMID: 10071101]
  111. J Neurotrauma. 2013 Dec 1;30(23):1966-72 [PMID: 23879560]
  112. Nature. 2008 Jul 24;454(7203):428-35 [PMID: 18650913]
  113. Neuroscience. 2015 Jan 29;285:215-26 [PMID: 25450954]
  114. Prog Neurobiol. 2015 Aug;131:65-86 [PMID: 26067058]
  115. Int J Mol Sci. 2013 Jan 14;14(1):1455-76 [PMID: 23344052]
  116. Trends Immunol. 2016 Aug;37(8):535-545 [PMID: 27424290]
  117. eNeuro. 2017 May 9;4(2): [PMID: 28497109]
  118. Epilepsy Res. 2011 Jun;95(1-2):20-34 [PMID: 21439793]
  119. Neurocrit Care. 2011 Aug;15(1):46-54 [PMID: 20878264]
  120. Brain. 2005 Oct;128(Pt 10):2396-407 [PMID: 15958506]
  121. Epilepsy Res. 2010 Jan;88(1):23-45 [PMID: 19850449]
  122. J Neurosci. 2001 Nov 1;21(21):8523-37 [PMID: 11606641]
  123. Neurochem Int. 2013 Nov;63(6):583-93 [PMID: 24076474]
  124. Neuropharmacology. 2013 Jun;69:16-24 [PMID: 22521336]
  125. Front Immunol. 2019 May 17;10:1048 [PMID: 31156629]
  126. J Neurochem. 2019 Dec;151(5):542-557 [PMID: 30644560]
  127. Brain Res Bull. 2012 Feb 10;87(2-3):180-6 [PMID: 22051612]
  128. Epilepsy Behav. 2013 Apr;27(1):115-7 [PMID: 23399946]
  129. J Neuroinflammation. 2018 May 22;15(1):154 [PMID: 29789012]
  130. Nat Rev Rheumatol. 2018 Sep;14(9):508-509 [PMID: 30108365]
  131. Exp Neurol. 2016 Jan;275 Pt 3:305-315 [PMID: 25828533]
  132. J Neurochem. 2008 Jul;106(1):1-23 [PMID: 18315560]
  133. J Neurosci Res. 1996 Aug 15;45(4):349-63 [PMID: 8872895]
  134. Trends Pharmacol Sci. 1997 Feb;18(2):59-62 [PMID: 9090312]
  135. Biomed Pharmacother. 2004 Jan;58(1):39-46 [PMID: 14739060]
  136. PLoS Med. 2009 Jul;6(7):e1000113 [PMID: 19636355]
  137. Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):4637-4642 [PMID: 30782788]
  138. Mol Neurobiol. 2009 Aug;40(1):15-32 [PMID: 19365736]
  139. PLoS One. 2012;7(4):e35050 [PMID: 22493728]
  140. J Signal Transduct. 2012;2012:646354 [PMID: 21977319]
  141. Epilepsia. 2014 Jan;55(1):17-25 [PMID: 24446952]
  142. Neurobiol Dis. 2018 Feb;110:102-121 [PMID: 29197620]
  143. J Neurotrauma. 2012 Mar 20;29(5):789-812 [PMID: 22023672]
  144. Oxid Med Cell Longev. 2016;2016:6023417 [PMID: 27006747]
  145. Free Radic Biol Med. 2004 Dec 15;37(12):1951-62 [PMID: 15544915]
  146. Front Cell Neurosci. 2019 Aug 08;13:307 [PMID: 31440141]
  147. Immunity. 2017 Jun 20;46(6):957-967 [PMID: 28636962]
  148. Ann Intensive Care. 2013 Jul 10;3(1):23 [PMID: 23837598]
  149. Nat Rev Neurol. 2010 Jul;6(7):393-403 [PMID: 20551947]
  150. J Neuropsychiatry Clin Neurosci. 2014 Apr 1;26(2):iv-113 [PMID: 24763802]
  151. Epilepsia. 2004 Oct;45(10):1202-9 [PMID: 15461674]
  152. Neurosurgery. 2002 Aug;51(2):289-301; discussion 302 [PMID: 12182767]
  153. J Cereb Blood Flow Metab. 2014 Nov;34(11):1736-48 [PMID: 25204393]
  154. Front Neurol. 2011 Mar 28;2:15 [PMID: 21625624]
  155. J Neurosci. 2013 Oct 2;33(40):15879-93 [PMID: 24089494]
  156. J Neurotrauma. 2002 Oct;19(10):1155-70 [PMID: 12427325]
  157. Purinergic Signal. 2008 Dec;4(4):339-46 [PMID: 18568425]
  158. Front Mol Neurosci. 2015 Jan 13;7:104 [PMID: 25628533]
  159. Epilepsia. 2001 Apr;42(4):515-24 [PMID: 11440347]
  160. Neurology. 2006 Jan 24;66(2):187-92 [PMID: 16434651]
  161. Curr Neuropharmacol. 2018;16(8):1224-1238 [PMID: 28606040]
  162. Neuroscience. 2016 May 26;323:157-69 [PMID: 25592426]
  163. Biomed Res Int. 2015;2015:745613 [PMID: 25650148]
  164. Nat Med. 1998 Jul;4(7):814-21 [PMID: 9662373]
  165. J Neurosurg. 1998 Dec;89(6):971-82 [PMID: 9833824]
  166. Epilepsia. 2006 Aug;47(8):1373-82 [PMID: 16922884]
  167. Handb Clin Neurol. 2015;127:3-13 [PMID: 25702206]
  168. Eur Cytokine Netw. 1998 Jun;9(2):131-8 [PMID: 9681388]
  169. Br J Pharmacol. 2012 Oct;167(4):699-719 [PMID: 23003569]
  170. Physiol Rev. 2013 Oct;93(4):1543-62 [PMID: 24137016]
  171. J Exp Med. 2019 Jan 7;216(1):60-70 [PMID: 30504438]
  172. J Neurotrauma. 2010 Jul;27(7):1283-95 [PMID: 20486807]
  173. J Neurophysiol. 2010 Mar;103(3):1490-500 [PMID: 20089815]
  174. J Neurotrauma. 2011 Jan;28(1):35-42 [PMID: 20836615]
  175. J Neurotrauma. 2014 Nov 15;31(22):1881-95 [PMID: 24927383]
  176. J Neurotrauma. 2010 May;27(5):889-99 [PMID: 20233041]
  177. J Neurosci. 1998 Oct 15;18(20):8356-68 [PMID: 9763479]
  178. Front Neurol. 2013 Mar 21;4:28 [PMID: 23519723]
  179. BMJ. 2006 Feb 11;332(7537):339-42 [PMID: 16470055]
  180. J Am Coll Cardiol. 1988 Sep;12(3):727-36 [PMID: 3403832]
  181. Cereb Cortex. 2012 Mar;22(3):595-606 [PMID: 21690263]
  182. J Thorac Dis. 2016 Jul;8(7):1406-9 [PMID: 27500853]
  183. Exp Neurol. 2009 Feb;215(2):243-52 [PMID: 19013458]
  184. Free Radic Res. 1999 Oct;31(4):261-72 [PMID: 10517532]
  185. Neuron. 2014 Jan 22;81(2):229-48 [PMID: 24462092]
  186. Lancet Neurol. 2017 Dec;16(12):987-1048 [PMID: 29122524]
  187. J Neurosurg. 2003 Mar;98(3):565-9 [PMID: 12650429]
  188. Neuron. 2017 Dec 20;96(6):1290-1302.e6 [PMID: 29268096]
  189. PLoS One. 2011;6(9):e24566 [PMID: 21931758]
  190. Front Pharmacol. 2019 Jun 07;10:638 [PMID: 31231224]
  191. World Neurosurg. 2019 Nov;131:126-132 [PMID: 31301445]
  192. Mol Neurobiol. 2018 Dec;55(12):9294-9306 [PMID: 29667129]
  193. J Neurochem. 2006 Apr;97(1):44-56 [PMID: 16515559]
  194. Epilepsy Res. 2010 Jun;90(1-2):47-59 [PMID: 20435440]
  195. J Neuropathol Exp Neurol. 2014 Jan;73(1):14-29 [PMID: 24335533]
  196. Braz J Med Biol Res. 2000 Oct;33(10):1141-8 [PMID: 11004714]
  197. Neurobiol Dis. 2019 Mar;123:86-99 [PMID: 29936231]
  198. J Neuroinflammation. 2018 Nov 21;15(1):323 [PMID: 30463579]
  199. Oncogene. 2008 Oct 20;27(48):6194-206 [PMID: 18931687]
  200. Brain. 2015 Aug;138(Pt 8):2399-422 [PMID: 26049087]
  201. J Neurosci. 2003 Sep 24;23(25):8692-700 [PMID: 14507968]
  202. J Neurosurg. 2010 May;112(5):1095-104 [PMID: 19731985]
  203. Antioxid Redox Signal. 2006 Sep-Oct;8(9-10):1583-96 [PMID: 16987013]
  204. Neurotherapeutics. 2014 Apr;11(2):401-11 [PMID: 24420312]
  205. Free Radic Biol Med. 2014 Nov;76:34-46 [PMID: 25091898]
  206. J Alzheimers Dis. 2010;20 Suppl 2:S413-26 [PMID: 20421693]
  207. Brain Dev. 1997 Jan;19(1):25-34 [PMID: 9071487]
  208. Neural Plast. 2012;2012:261345 [PMID: 22530155]
  209. Immunity. 2017 Jun 20;46(6):943-956 [PMID: 28636961]
  210. J Neuroinflammation. 2018 Jan 22;15(1):24 [PMID: 29357880]
  211. Neural Regen Res. 2019 Oct;14(10):1701-1702 [PMID: 31169179]
  212. J Neuroinflammation. 2020 Apr 6;17(1):104 [PMID: 32252777]
  213. Neurobiol Dis. 2012 Dec;48(3):429-38 [PMID: 22766033]
  214. Antioxid Redox Signal. 2015 Aug 10;23(5):358-74 [PMID: 26135714]
  215. Front Neurosci. 2018 Dec 20;12:981 [PMID: 30618597]
  216. CNS Neurol Disord Drug Targets. 2006 Oct;5(5):561-8 [PMID: 17073658]
  217. Mol Brain. 2011 Nov 22;4:42 [PMID: 22107761]
  218. Biochim Biophys Acta. 1995 Apr 6;1266(1):31-44 [PMID: 7718619]
  219. Trends Pharmacol Sci. 1998 Aug;19(8):328-34 [PMID: 9745361]
  220. Cell Mol Life Sci. 2004 Aug;61(16):2031-45 [PMID: 15316653]
  221. Neuropsychiatr Dis Treat. 2016 Oct 12;12:2605-2616 [PMID: 27789949]
  222. Front Pharmacol. 2020 Jan 14;10:1532 [PMID: 32009953]
  223. Clin Neurol Neurosurg. 2006 Jul;108(5):433-9 [PMID: 16225987]
  224. J Alzheimers Dis. 2019;72(1):161-180 [PMID: 31561367]
  225. J Neural Transm (Vienna). 2012 Aug;119(8):891-910 [PMID: 22212484]
  226. Neurobiol Dis. 2020 Jul;141:104952 [PMID: 32442681]
  227. Am J Transl Res. 2020 Oct 15;12(10):6351-6365 [PMID: 33194035]
  228. Neuropathol Appl Neurobiol. 2013 Feb;39(1):35-44 [PMID: 23206160]
  229. Brain Struct Funct. 2017 Apr;222(3):1543-1556 [PMID: 27586142]
  230. Nat Neurosci. 2005 Jun;8(6):752-8 [PMID: 15895084]
  231. Curr Med Chem. 2007;14(11):1189-97 [PMID: 17504139]
  232. Front Pharmacol. 2012 Apr 12;3:60 [PMID: 22518104]
  233. Neurobiol Dis. 2015 Jun;78:115-25 [PMID: 25836421]
  234. Viral Immunol. 2005;18(1):41-78 [PMID: 15802953]
  235. Expert Rev Neurother. 2016;16(2):123-30 [PMID: 26689339]
  236. J Neurosci. 2017 Apr 26;37(17):4450-4461 [PMID: 28330876]
  237. Glia. 2012 Aug;60(8):1258-68 [PMID: 22331574]
  238. Brain. 2004 Feb;127(Pt 2):304-14 [PMID: 14607786]
  239. Eur J Neurosci. 2019 May;49(9):1157-1170 [PMID: 30554430]
  240. Exp Neurol. 2018 Jan;299(Pt A):228-240 [PMID: 28455196]
  241. J Infect Dis. 2014 Mar;209(6):960-70 [PMID: 24218508]
  242. Epilepsy Behav. 2005 Dec;7(4):569-77 [PMID: 16246628]
  243. Neurosurg Focus. 2012 Mar;32(3):E10 [PMID: 22380851]
  244. Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3591-6 [PMID: 23401547]
  245. Ann Neurol. 2020 Apr;87(4):497-515 [PMID: 32031699]
  246. Neuroscience. 2020 Jan 21;428:140-153 [PMID: 31866558]
  247. Exp Neurol. 2019 Jul;317:260-270 [PMID: 30926390]
  248. Front Cell Neurosci. 2016 Feb 29;10:43 [PMID: 26973460]
  249. Antioxid Redox Signal. 2013 Feb 10;18(5):522-55 [PMID: 22667998]
  250. Neurosci Lett. 1998 Dec 18;258(2):73-6 [PMID: 9875530]
  251. J Cell Mol Med. 2008 Oct;12(5B):1830-47 [PMID: 18554314]
  252. Epilepsy Curr. 2018 Sep-Oct;18(5):304-306 [PMID: 30464729]
  253. Clin Cancer Res. 2005 May 1;11(9):3155-62 [PMID: 15867207]
  254. Antiviral Res. 2013 Jun;98(3):373-9 [PMID: 23603497]
  255. Arch Neurol. 2000 Nov;57(11):1611-6 [PMID: 11074793]
  256. J Biol Chem. 2010 Jul 16;285(29):22244-53 [PMID: 20463017]
  257. Ann Clin Lab Sci. 2012 Winter;42(1):26-33 [PMID: 22371907]
  258. Cardiovasc Psychiatry Neurol. 2011;2011:765923 [PMID: 21436875]
  259. Acta Neurol Taiwan. 2010 Mar;19(1):3-15 [PMID: 20711885]
  260. Am J Pathol. 2020 Mar;190(3):535-542 [PMID: 31866349]
  261. Cell Mol Life Sci. 2000 Aug;57(8-9):1287-305 [PMID: 11028919]
  262. Arch Neurol. 2008 May;65(5):619-26 [PMID: 18474737]
  263. J Neurotrauma. 2020 Jun 15;37(12):1463-1480 [PMID: 32056479]
  264. Immunity. 2016 Mar 15;44(3):450-462 [PMID: 26982353]
  265. Arch Virol. 2013 Aug;158(8):1755-64 [PMID: 23525700]
  266. J Neuroinflammation. 2019 Aug 5;16(1):163 [PMID: 31383034]
  267. J Neurosci. 1999 Jun 15;19(12):5054-65 [PMID: 10366638]
  268. Exp Neurol. 2020 Sep;331:113372 [PMID: 32504636]
  269. Neuropharmacology. 2019 Feb;145(Pt B):230-246 [PMID: 30086289]
  270. Neuropharmacology. 2019 Feb;145(Pt B):259-267 [PMID: 30075158]
  271. J Neuroimmunol. 2015 Dec 15;289:143-51 [PMID: 26616884]
  272. Oxid Med Cell Longev. 2019 Jul 3;2019:6380473 [PMID: 31354910]
  273. Neuropsychiatr Dis Treat. 2014 Aug 11;10:1469-77 [PMID: 25143737]
  274. Nat Immunol. 2008 Sep;9(9):1037-46 [PMID: 18641654]
  275. Epilepsy Res. 2010 Jan;88(1):55-64 [PMID: 19864112]
  276. Neurotherapeutics. 2010 Jan;7(1):3-12 [PMID: 20129492]
  277. PLoS One. 2013 May 14;8(5):e64078 [PMID: 23691153]
  278. Front Cell Neurosci. 2019 Jun 28;13:282 [PMID: 31316352]
  279. J Neuroinflammation. 2018 May 15;15(1):144 [PMID: 29764485]
  280. J Neurosurg. 2016 Sep;125(3):631-41 [PMID: 26722854]
  281. Semin Cell Dev Biol. 2016 Jun;54:42-52 [PMID: 26541482]
  282. Acta Neuropathol. 2016 Feb;131(2):211-234 [PMID: 26423537]
  283. Nat Rev Neurosci. 2004 Apr;5(4):317-28 [PMID: 15034556]
  284. Redox Rep. 2010;15(1):2-10 [PMID: 20196923]
  285. Pharmacogn Rev. 2010 Jul;4(8):118-26 [PMID: 22228951]
  286. Free Radic Biol Med. 2013 Sep;62:121-131 [PMID: 23411150]
  287. Nat Rev Drug Discov. 2008 Sep;7(9):759-70 [PMID: 18758473]
  288. Behav Brain Res. 2008 Nov 21;193(2):306-10 [PMID: 18573545]
  289. Neural Regen Res. 2019 Sep;14(9):1481-1489 [PMID: 31089036]
  290. J Neuroinflammation. 2017 Jan 13;14(1):10 [PMID: 28086980]
  291. Neurochem Res. 2019 Mar;44(3):661-675 [PMID: 28836168]
  292. Mol Neurobiol. 2015;51(3):966-79 [PMID: 24865512]
  293. Mol Cells. 2011 Dec;32(6):491-509 [PMID: 22207195]
  294. Cereb Cortex. 2015 Aug;25(8):2306-20 [PMID: 24610117]
  295. Epilepsia. 1994 Jul-Aug;35(4):728-36 [PMID: 7521835]

Word Cloud

Created with Highcharts 10.0.0PTETBIbrainepilepsychangesinjuryrisktimemaypost-traumaticmechanismsstrategiesdiscussnovelfactorsimmuneresponsemanagementTraumaticleadingcausedeathyoungadultsfactoracquiredSevereperiodcausesnumerousneuropsychiatricneurodegenerativeproblemsvaryingcomorbiditieshomeostasisneverrestoredconsequencedisruptedequilibriumneuropathologicalcircuitremodelingreorganizationneuralnetworksstructuralfunctionalplasticitypredispositionsynchronizedactivitypost-translationalmodificationsynapticproteinsbegindominatepathologicalcoursecontributeconditionslikeAlzheimerdiseasedementiaanxietydisordersonecommondevastatingcomplicationsaffectedsevere50%developetiopathologyeitherunknownpoorlyunderstoodmakestreatmentchallengingAlthoughanti-epilepticdrugsAEDsusedpreventivemanagecontrolacuteseizurespreventdevelopmentefficacyremainscontroversialreviewunderlyingalsodysfunctionsneurovascularunitcell-specificneuroinflammatorymediatorsvitalepileptogenesisFinallydescribecurrenttreatmentspreventingNeuropathophysiologicalMechanismsTreatmentStrategiesPost-traumaticEpilepsyclinicalexcitotoxicityneurodegenerationneuroinflammationoxidativestresstraumatic

Similar Articles

Cited By